The University of Wisconsin Fundus Photograph Reading Center (UW FPRC) proposes to serve as photograph reading center for the DME Clinical Research Network. To accomplish this, we propose to: (I) Collaborate with other network investigators to develop ideas for clinical trials of promising new DME treatments, construct study protocols, carry out approved studies, analyze the resultant data, and prepare manuscripts. (2) Adapt or develop procedures for documenting and grading DME. We can provide protocols for DME imaging (color stereoscopic fundus photographs, fluorescein angiograms, and optical coherence tomograms), and are experienced at orienting, certifying, and giving feedback to clinic photographers. By extending the Early Treatment Diabetic Retinopathy Study classification, we have protocols for evaluation/grading of DME from color photographs and angiograms. We are developing a protocol for assessment of OCT scans. We are prepared to modify these protocols further, if necessary, to define the eligibility and outcome criteria appropriate to network goals. The UW FPRC principal investigator and staff are experienced at participation in collaborative multi-center clinical trials (e.g., Diabetic Retinopathy Study, Early Treatment of Diabetic Retinopathy Study, Diabetes Control and Complications Trial, and several drug trials) and in networks to conduct them (e.g., the Study of the Ocular Complications of AIDS), and are strongly committed to the study of DME and its potential treatments as a major public health priority.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10EY014229-06
Application #
7221205
Study Section
Special Emphasis Panel (ZEY1-VSN (03))
Program Officer
Everett, Donald F
Project Start
2002-09-30
Project End
2008-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
6
Fiscal Year
2007
Total Cost
$409,447
Indirect Cost
Name
University of Wisconsin Madison
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Wang, Tiansheng; Hong, Jin-Liern; Gower, Emily W et al. (2018) Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care 41:1998-2009
Wells, John A; Glassman, Adam R; Ayala, Allison R et al. (2017) Reply. Ophthalmology 124:e5-e6
Beaulieu, Wesley T; Bressler, Neil M; Melia, Michele et al. (2016) Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Am J Ophthalmol 170:206-213
Wells, John A; Glassman, Adam R; Ayala, Allison R et al. (2016) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 123:1351-9
Bressler, Susan B; Almukhtar, Talat; Bhorade, Anjali et al. (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589-97
Elman, Michael J; Ayala, Allison; Bressler, Neil M et al. (2015) Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:375-81
Jampol, Lee M; Bressler, Neil M; Glassman, Adam R (2014) Revolution to a new standard treatment of diabetic macular edema. JAMA 311:2269-70
Bressler, Susan B; Qin, Haijing; Melia, Michele et al. (2013) Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 131:1033-40
Bressler, Susan B; Almukhtar, Talat; Aiello, Lloyd P et al. (2013) Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network. Retina 33:2080-8
Bhavsar, Abdhish R; Stockdale, Cynthia R; Ferris 3rd, Frederick L et al. (2012) Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 130:809-10

Showing the most recent 10 out of 52 publications